Truvada as PrEP Does Not Cause Kidney Damage, Study Suggests
Taking tenofovir/emtricitabine (Truvada) as pre-exposure prophylaxis (PrEP) has little effect on kidney function, according to a study recently published in AIDS. The study, known as IPrEx (Iniciativa Profilaxis Pre-Exposicion), showed a very mild decrease in creatinine clearance (CrCl)—a measure of kidney function—among participants taking Truvada, but the change was reversible, as CrCl returned to baseline levels after the drug was discontinued at the end of the study.